Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population

Michael D Kappelman, Kristen R Moore, Jeffery K Allen, Suzanne F Cook, Michael D Kappelman, Kristen R Moore, Jeffery K Allen, Suzanne F Cook

Abstract

Purpose: Most US inflammatory bowel disease (IBD) epidemiology studies conducted to date have sampled small, geographically restricted populations and have not examined time trends. The aim of our study was to determine the prevalence of Crohn's disease (CD) and ulcerative colitis (UC) in a commercially insured US population and compare prevalences across sociodemographic characteristics and time.

Methods: Using claims data from approximately 12 million Americans, we performed three consecutive 2-year cross-sectional studies. Cases of CD and UC were identified using a previously described algorithm. Prevalence was estimated by dividing cases by individuals in the source population. Logistic regression was used to compare prevalences by region, age, and sex.

Results: In 2009, the prevalences of CD and UC in children were 58 [95 % confidence interval (CI) 55-60] and 34 (95 % CI 32-36), respectively. In adults, the respective prevalences were 241 (95 % CI 238-245) and 263 (95 % CI 260-266). Data analysis revealed that IBD prevalences have slightly increased over time. Based on census data, an estimated 1,171,000 Americans have IBD (565,000 CD and 593,000 UC).

Conclusions: Analysis of the epidemiological data revealed an increasing burden of IBD in recent years, which may be used to inform policy.

Figures

Fig. 1
Fig. 1
Age-specific prevalence of Crohn’s disease (CD) per 100,000 persons in a commercially insured US population, 2008–2009
Fig. 2
Fig. 2
Age-specific prevalence of ulcerative colitis (UC) per 100,000 persons in a commercially insured US population, 2008–2009
Fig. 3
Fig. 3
Standardized prevalence estimates of CD per 100,000 persons in a commercially insured US population by age group, 2004–2009
Fig. 4
Fig. 4
Standardized prevalence estimates of UC per 100,000 persons in a commercially insured US population by age group, 2004–2009

References

    1. Herrinton LJ, Liu L, Lafata JE, et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis. 2007;13:451–461. doi: 10.1002/ibd.20021.
    1. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a northern California managed care organization, 1996–2002. Am J Gastroenterol. 2008;103:1998–2006. doi: 10.1111/j.1572-0241.2008.01960.x.
    1. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429. doi: 10.1016/j.cgh.2007.07.012.
    1. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003;143:525–531. doi: 10.1067/S0022-3476(03)00444-X.
    1. Loftus CG, Loftus EV, Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted county, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–261. doi: 10.1002/ibd.20029.
    1. Abramson O, Durant M, Mow W, et al. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in northern California, 1996 to 2006. J Pediatr. 2010;157:233.e1–239.e1.
    1. Stempel DA, Mauskopf J, McLaughlin T, Yazdani C, Stanford RH. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med. 2001;95:227–234. doi: 10.1053/rmed.2000.1027.
    1. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn’s disease and ulcerative colitis in a central canadian province: a population-based study. Am J Epidemiol. 1999;149:916–924. doi: 10.1093/oxfordjournals.aje.a009735.
    1. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913. doi: 10.1053/j.gastro.2008.09.012.
    1. Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare resources by US children and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:62–68. doi: 10.1002/ibd.21371.
    1. Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn’s disease in a commercially-insured setting. Am J Ther. 2006;13:502–506. doi: 10.1097/01.mjt.0000245223.43783.45.
    1. Cohen RD, Waters HC, Tang B, Rahman MI. Effects of fistula on healthcare costs and utilization for patients with Crohn’s disease treated in a managed care environment. Inflamm Bowel Dis. 2008;14:1707–1714. doi: 10.1002/ibd.20530.
    1. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol. 2006;101:1559–1568. doi: 10.1111/j.1572-0241.2006.00603.x.
    1. Ingle SB, Loftus EV, Tremaine WJ, et al. Increasing incidence and prevalence of inflammatory bowel disease in Olmsted county, Minnesota, during 2001–2004. Gastroenterology. 2007;132:A19–A20.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit